Bausch Health Companies Inc (BHC)vsZoetis Inc (ZTS)
BHC
Bausch Health Companies Inc
$5.08
+1.80%
HEALTHCARE · Cap: $1.85B
ZTS
Zoetis Inc
$116.71
+0.67%
HEALTHCARE · Cap: $51.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Bausch Health Companies Inc generates 8% more annual revenue ($10.27B vs $9.47B). ZTS leads profitability with a 28.2% profit margin vs 1.5%. BHC appears more attractively valued with a PEG of 0.01. BHC earns a higher WallStSmart Score of 69/100 (B-).
BHC
Strong Buy69
out of 100
Grade: B-
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.1%
Fair Value
$19.66
Current Price
$5.08
$14.58 discount
Margin of Safety
-29.1%
Fair Value
$99.69
Current Price
$116.71
$17.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Attractively priced relative to earnings
Every $100 of equity generates 44 in profit
Conservative balance sheet, low leverage
Strong operational efficiency at 25.8%
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Smaller company, higher risk/reward
1.5% margin — thin
Distress zone — elevated risk
Expensive relative to growth rate
Trading at 14.9x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BHC
The strongest argument for BHC centers on PEG Ratio, P/E Ratio, Return on Equity. PEG of 0.01 suggests the stock is reasonably priced for its growth.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : BHC
The primary concerns for BHC are Market Cap, Profit Margin, Altman Z-Score. Thin 1.5% margins leave little buffer for downturns.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
ZTS carries more volatility with a beta of 0.95 — expect wider price swings.
BHC is growing revenue faster at 9.3% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BHC scores higher overall (69/100 vs 64/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bausch Health Companies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Bausch Health Companies Inc. develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology and dermatology. The company is headquartered in Laval, Canada.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?